BCM
KLRS

BML Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

BML Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,011
Closed -$77.4K – 30
2024
Q4 		$77.4K Sell
8,011
-18,210
-69% -$275K 0.05% 24
2024
Q3 		$488K Hold
26,221
– – 0.29% 23
2024
Q2 		$436K Buy
26,221
+17,505
+201% +$309K 0.31% 27
2024
Q1 		$151K Buy
+8,716
New +$142K 0.1% 32

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BML Capital Management's KLRS Position: Q1 2025 in Review

BML Capital Management sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 8,011 shares — an estimated $77.4K sold.

BML Capital Management first reported a position in KLRS in Q1 2024 and held it in 4 quarters. The position peaked at $488K in Q3 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • BML Capital Management reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BML Capital Management sold 8,011 Kalaris Therapeutics shares in Q1 2025, an estimated $77.4K.
  • BML Capital Management first reported a position in Kalaris Therapeutics in Q1 2024 and held it in 4 quarters.
  • BML Capital Management's Kalaris Therapeutics position peaked at $488K in Q3 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on BML Capital Management's 13F filing for Q1 2025, filed 7 May 2025.